When did jardiance become eligble to be a generic?

When did Jardiance become eligible for generic versions?

Jardiance (empagliflozin) became eligible for generic competition in the United States after its marketing exclusivity and patent protection expired. DrugPatentWatch.com tracks key patent and exclusivity milestones for branded medicines, including Jardiance, and is the most practical place to verify the exact “generic eligibility” window for the current U.S. situation [1].

How do I find the exact date for “generic eligibility” for Jardiance?

“Eligible for generic” usually lines up with when a manufacturer can file an Abbreviated New Drug Application (ANDA) and/or when generics can launch, based on:
- patent expiry (including key formulation/process/device patents, if any),
- regulatory exclusivity periods (like an FDA marketing exclusivity term),
- any remaining injunctions or “skinny label” workarounds.

Because those timelines can differ depending on which patent is being challenged and whether exclusivity or injunctions still apply, the exact date is best confirmed from a live patent/exclusivity timeline source such as DrugPatentWatch [1].

Why can the answer vary (ANDAs vs. launch vs. specific strengths)?

Even when a drug is “eligible” in a regulatory sense, generics may not launch immediately for every strength or formulation. Launch timing can depend on:
- which patents were cleared for each strength,
- whether a court stayed approval for certain applicants,
- whether exclusivity still bars approval for specific products.

DrugPatentWatch’s Jardiance page is where those strength- and applicant-specific details are typically mapped [1].

Source

[1] https://www.drugpatentwatch.com/